Clermont Group
VC Fund
Singapore, Singapore
Clermont Group is a VC fund in Singapore focused on Pharmaceutical and Banking. The Clermont Group is a private investment group based in Singapore. Since 1986, they have invested globally in public and private equity across a range of industries, including energy, financial services, consumer, and healthcare.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 63%
Last updated:
For AI agents: llms.txt
Industries Clermont Group invests in
PharmaceuticalBankingFinanceMedicalHealth Care
Stages Clermont Group invests in
Series ASeries BPrivate EquityVenture - Series Unknown
Countries Clermont Group invests in
IndiaIsraelIndonesiaUnited StatesUnited Kingdom
Round sizes
Series B $100M–$214MPrivate Equity $130M–$440M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $100M–$214M
- Private Equity
- $130M–$440M
Investment Focus
Industry
- Pharmaceutical 3 (38%)
- Banking 2 (25%)
- Finance 2 (25%)
- Medical 2 (25%)
- Health Care 2 (25%)
Stage
- Series A 2 (25%)
- Series B 2 (25%)
- Private Equity 2 (25%)
- Venture - Series Unknown 1 (13%)
Country
- India 2 (25%)
- Israel 1 (13%)
- Indonesia 1 (13%)
- United States 1 (13%)
- United Kingdom 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
John Mescall
Founder & Managing Director
|
Founder & Managing Director | Total investments: 0 | Find email | |
Richard Watkins
Country Head, UAE
|
Country Head, UAE | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| PostEra uses machine learning to close the design-make-test loop of drug discovery and reduce our clients' cycle times. We are currently leading an international team of scientists to find a COVID antiviral via on open science initative. Consider contributing your expertise to the initiative here: https://postera.ai/covid | $24M / Series A / Jan 11, 2022 | ||
| OakNorth had a fundamental purpose: to serve and empower established small-to-medium sized businesses (SMEs) that were seeking to scale but were routinely underserved or overlooked by traditional banks: what it calls the ‘Missing Middle’. Its founders, Rishi Khosla and Joel Perlman, had experienced this first-hand while scaling their previous company - Copal. In 2015, three years after launching that business, they applied for a bank loan and the ‘computer said ‘no’’, despite their business being profitable. The products, services, and experience needed to make their lives as a scaling business easier, and enable them to reach their full potential, were ‘missing’ from banks’ offerings. As entrepreneurs, their response was to build what was missing: a neobank for entrepreneurs, by entrepreneurs. To date, its bespoke debt finance solutions have supported property developers, care homes, specialist schools and nurseries, hotels, bars and restaurants, pub operators, as well as fund and specialist finance providers. With a range of specialist secured and unsecured business loans, OakNorth caters to the growth plans of businesses, without asking them to give up equity. Despite experiencing not one, but two unprecedented events – Brexit and COVID-19 – since its launch, the bank has continued supporting growth businesses across the UK. It’s lent over £10 billion to date, directly helping with the creation of almost tens of thousands of new jobs and new homes (the significant majority of which are affordable and social housing). Its data-led approach allows it to look at the future, rather than just fixating on the past, meaning it avoids making decisions based on outdated financials. Using data and analytics, it builds up a granular view of every business in its portfolio, combining this with forward-looking scenario analysis, to enable it to be a trusted funding partner as the business scales, and continue confidently lending through economic cycles and unprecedented events. By behaving as reliable, long-term partners to its customers throughout the pandemic, rather than just bankers, it has been able to make them its best advocates. As a result, c.80% of its new lending comes via referrals, and 40% of its borrowers are repeat customers. | $440M / Private Equity / Feb 08, 2019 | ||
| With the goal of making clean regional air travel accessible for all, Eviation, a global manufacturer of all-electric air mobility solutions, is tackling one of the world’s dirtiest industries - aviation - with a zero-emissions solution, it’s Alice aircraft. Since its launch in June 2017, Eviation has been aggressively moving ahead with strategicpartners to develop, design and manufacture the first all-electric propulsion aircraft.READ MORE:The Alice, which debuted at the 52nd Paris Air Show in June 2017, leverages an IP portfolio that includes thermal management and autonomous landing, as well as distributed electric propulsion, industry-leading battery technology, and cutting-edge composite body frames capable of carrying up to 9 passengers on a single charge for 650 miles. Because it is already compliant with existing FAA regulations and boasts incredible cost cuts in terms operational lifetime, the Alice is primed to make regional air travel emissions-free and fully electric. In 2018, Eviation established U.S. headquarters in Prescott, Arizona to expand operations as it targets the U.S. as a lucrative market for its electric commuter aircraft. Eviation is pioneering accessible sustainable air travel that will power the future of regional transit. | $140M / Series B / Jan 20, 2019 | ||
| OakNorth had a fundamental purpose: to serve and empower established small-to-medium sized businesses (SMEs) that were seeking to scale but were routinely underserved or overlooked by traditional banks: what it calls the ‘Missing Middle’. Its founders, Rishi Khosla and Joel Perlman, had experienced this first-hand while scaling their previous company - Copal. In 2015, three years after launching that business, they applied for a bank loan and the ‘computer said ‘no’’, despite their business being profitable. The products, services, and experience needed to make their lives as a scaling business easier, and enable them to reach their full potential, were ‘missing’ from banks’ offerings. As entrepreneurs, their response was to build what was missing: a neobank for entrepreneurs, by entrepreneurs. To date, its bespoke debt finance solutions have supported property developers, care homes, specialist schools and nurseries, hotels, bars and restaurants, pub operators, as well as fund and specialist finance providers. With a range of specialist secured and unsecured business loans, OakNorth caters to the growth plans of businesses, without asking them to give up equity. Despite experiencing not one, but two unprecedented events – Brexit and COVID-19 – since its launch, the bank has continued supporting growth businesses across the UK. It’s lent over £10 billion to date, directly helping with the creation of almost tens of thousands of new jobs and new homes (the significant majority of which are affordable and social housing). Its data-led approach allows it to look at the future, rather than just fixating on the past, meaning it avoids making decisions based on outdated financials. Using data and analytics, it builds up a granular view of every business in its portfolio, combining this with forward-looking scenario analysis, to enable it to be a trusted funding partner as the business scales, and continue confidently lending through economic cycles and unprecedented events. By behaving as reliable, long-term partners to its customers throughout the pandemic, rather than just bankers, it has been able to make them its best advocates. As a result, c.80% of its new lending comes via referrals, and 40% of its borrowers are repeat customers. | $100M / Series B / Sep 06, 2018 | ||
| Indiabulls Pharmaceuticals was incorporated in July 2016 with an ambition to become a leading provider of healthcare products and services in India and beyond. The Indian healthcare sector is poised for significant growth in the coming decade driven by rising incomes, enhanced medical infrastructure, rise in the prevalence and treatment of chronicdiseases and greater health insurance. Specifically, the Indian pharmaceutical market is projected to grow to USD 55 billion by 20201 from a current estimated size of USD 27 billion and this will take the Indian pharmaceutical market in the top 5 global market both in terms of volume and value. The secular growth of the industry is further bolstered by the commitment of the Indian government to increase access for patients and provide benefits for investments in manufacturing and research and development for the manufacturers. | $24M / Venture - Series Unknown / Dec 06, 2017 | ||
| New-age financial services institution focused on providing credit to small businesses and consumers. | $130M / Private Equity / Nov 02, 2017 | ||
| OakNorth had a fundamental purpose: to serve and empower established small-to-medium sized businesses (SMEs) that were seeking to scale but were routinely underserved or overlooked by traditional banks: what it calls the ‘Missing Middle’. Its founders, Rishi Khosla and Joel Perlman, had experienced this first-hand while scaling their previous company - Copal. In 2015, three years after launching that business, they applied for a bank loan and the ‘computer said ‘no’’, despite their business being profitable. The products, services, and experience needed to make their lives as a scaling business easier, and enable them to reach their full potential, were ‘missing’ from banks’ offerings. As entrepreneurs, their response was to build what was missing: a neobank for entrepreneurs, by entrepreneurs. To date, its bespoke debt finance solutions have supported property developers, care homes, specialist schools and nurseries, hotels, bars and restaurants, pub operators, as well as fund and specialist finance providers. With a range of specialist secured and unsecured business loans, OakNorth caters to the growth plans of businesses, without asking them to give up equity. Despite experiencing not one, but two unprecedented events – Brexit and COVID-19 – since its launch, the bank has continued supporting growth businesses across the UK. It’s lent over £10 billion to date, directly helping with the creation of almost tens of thousands of new jobs and new homes (the significant majority of which are affordable and social housing). Its data-led approach allows it to look at the future, rather than just fixating on the past, meaning it avoids making decisions based on outdated financials. Using data and analytics, it builds up a granular view of every business in its portfolio, combining this with forward-looking scenario analysis, to enable it to be a trusted funding partner as the business scales, and continue confidently lending through economic cycles and unprecedented events. By behaving as reliable, long-term partners to its customers throughout the pandemic, rather than just bankers, it has been able to make them its best advocates. As a result, c.80% of its new lending comes via referrals, and 40% of its borrowers are repeat customers. | $213.5M / Series B / Oct 12, 2017 | ||
| HaloDoc is a healthcare network platform. HaloDoc connects users to a network of 19,000 licensed doctors, 1,000 certified partner pharmacies through medical delivery service ApotikAntar, and licensed medical laboratory services. Users can communicate with these medical professionals via chat, video and voice call. | Series A / Sep 09, 2016 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FinTech Investors
49,400 investors
Health Care Investors
48,825 investors
Medical Investors
21,329 investors
Finance Investors
17,738 investors
FinTech VC Funds
32,946 investors
Health Care VC Funds
36,610 investors
Medical VC Funds
18,339 investors
Finance VC Funds
13,317 investors
FinTech Investors in United States
21,806 investors
FAQ
What does Clermont Group invest in?
Clermont Group invests primarily in Pharmaceutical, Banking and Finance startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Clermont Group invest in?
Clermont Group typically joins rounds of $100M–$214M at Series B and $130M–$440M at Private Equity. These are whole funding-round sizes, not Clermont Group's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Clermont Group took part in.
How do I contact Clermont Group?
Public channels for Clermont Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Clermont Group?
The team at Clermont Group includes John Mescall (Founder & Managing Director) and Richard Watkins (Country Head, UAE). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
